This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Kips Bay Medical Announces First Enrollments In Its European Post Market Studies

Kips Bay Medical (NASDAQ: KIPS) announced that the first patients have been enrolled in the Company sponsored eSVS MESH Post-Market Randomized Study at the University Hospital Kiel in Germany by Dr. Tim Attmann who stated, “We are pleased to have been the first center to start enrolling patients in this important post-market study. These two patients were typical surgery candidates with symptomatic multiple coronary artery disease, each requiring three (3) coronary artery bypass grafts.”

The intent of the post-market study is to evaluate short term and long term patency of saphenous vein grafts treated with the eSVS MESH during coronary artery bypass surgery. The clinical studies will involve several prestigious cardiovascular centers across Europe. The data from these studies will be used to further support the marketing of and reimbursement requirements for the eSVS MESH internationally.

Commenting on the start of the Study, Professor, Dr. Joachim Cremer, Chief, Department of Cardiovascular Surgery, at the University Hospital Kiel stated, “The eSVS Mesh concept of supporting the vein graft to prevent over-expansion and subsequent vessel injury is very intriguing and could lead to improved patient outcomes and that’s what this study is designed to demonstrate.” Professor Cremer and his colleagues had previously participated in the multicenter international clinical trial of the eSVS MESH which led to CE Mark approval in May 2010.

This first study will be prospective multi-center, randomized, controlled, clinical study of up to 200 patients, designed to evaluate the short and long term patency of the eSVS MESH compared with a an untreated control graft. In this study each patient will have both a saphenous vein graft treated with the eSVS MESH and untreated graft implanted during their coronary artery bypass surgery. The location of the saphenous vein graft treated with the eSVS MESH will be randomized to either the right or circumflex coronary artery bed. Patency will be assessed at 6 months and 2 years post implant.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,055.29 -15.93 -0.09%
S&P 500 1,975.65 -2.15 -0.11%
NASDAQ 4,496.5090 -9.3430 -0.21%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs